San Diego State University

Novartis AG said when it disclosed that preclinical safety data for Zolgensma were manipulated in the biologic license application for the gene therapy that the company would be "exiting" employees i

Tracking the progress of a group of biotechs founded in the late ’90s yields some important lessons for today’s entrepreneurs. Nancy Dvorin and Melanie Senior Laying out a strategy is one thing; execu

QUESTION: Will the emergence of new biological targets as a result of genomics and proteomics change venture investors' long-held perception that diagnostics is a low-margin business that poses signif

Targeting the essential genes of pathogens We first spoke to Elitra Pharmaceuticals Inc. shortly after its inception as RajaBiotics in 1997 ( see "Effecting New Antibiotics, Part II: Microbial Gen